



## Factors associated with visit-to-visit variability of blood pressure in hypertensive patients at a Primary Health Care Service, Tabanan, Bali, Indonesia

Gusti Ayu Riska Pertiwi<sup>1</sup>, Anak Agung Ngurah Aryawangsa<sup>1</sup>, I Putu Yuda Prabawa<sup>2</sup>, Ida Bagus Amertha Putra Manuaba<sup>3,4</sup>, Agha Bhargah<sup>1</sup>, Ni Wayan Sri Ratni<sup>5</sup>, I Putu Gede Budiana<sup>6</sup>

### Abstract

**Background:** An increasing number of valid and well-designed trials have demonstrated a positive correlation between visit-to-visit variability (VTV) in systolic blood pressure (SBP) and increased risk of stroke and coronary heart disease among hypertensive patients.

**Methods:** A cross-sectional study was conducted that involved 74 patients who visited the outpatient clinic at the Tabanan III Primary Health Care Service during April to May 2017. Blood pressure was retrospectively obtained from medical records. VTV was classified as low or high on the basis of the standard deviation of SBP. Antihypertensive medication adherence was expressed as the percentage of days covered, and sodium intake was measured with 24-hour food recall. Bivariate analysis was performed, followed by multivariate analysis for significant variables.

**Results:** Among the participants, 67.6% were female, with a mean (standard deviation [SD]) age of 62.70 (10.00) years. Blood pressure was measured  $4.82 \pm 0.78$  times during the period, and the mean (SD) SBP was 139.65 (10.57) mm Hg. Nonadherence and sodium intake were significantly higher in the high-VTV group than in the low-VTV group (nonadherence 13.5% vs. 37.8%,  $P=0.033$ ; sodium intake  $1278.44 \pm 43.02$  mg vs.  $1495.85 \pm 45.26$  mg,  $P=0.038$ ). After adjustment for other covariates, the differences remained significant only for nonadherence (model I  $\exp \beta=3.89$  [95.0% confidence interval 1.23–12.34,  $P<0.05$ ], model II  $\exp \beta=3.9$  [95.0% confidence interval 1.12–14.15,  $P<0.05$ ]). The area under the curve was 0.636 ( $P<0.05$ ), with sensitivity of 67.6% and specificity of 51.4%.

**Conclusion:** Nonadherence to antihypertensive medication was significantly associated with higher VTV of SBP. Further study is needed to assess whether improving adherence could reduce VTV and improve cardiovascular outcomes.

**Keywords:** Blood pressure; visit-to-visit-variability; nonadherence; sodium intake; hypertension

**Significance statement:** This study provides an overview of visit-to-visit variability (VTV) in hypertension blood pressure management in a primary health care service setting. In this study there was a significant relationship between the use of antihypertensive drugs and VTV. This finding illustrates that VTV can be used as an additional factor in considering the target of controlling blood pressure in primary health services, given that hypertension has many complications that can arise if management is not done properly.

1. Faculty of Medicine, Udayana University, P.B. Sudirman Street, Dangin Puri Klod, West Denpasar, Denpasar City, Bali 80232, Indonesia

2. Biomedicine Magister Program, Post Graduate Program, Faculty of Medicine, Udayana University, P.B. Sudirman Street, Dangin Puri Klod, West Denpasar, Denpasar City, Bali 80232, Indonesia

3. Medical and Health Education, Faculty of Medicine, Udayana University, P.B. Sudirman Street, Dangin Puri Klod, West Denpasar, Denpasar City, Bali 80232, Indonesia

4. International Program in Medicine, College of Medicine, Taipei Medical University, No. 250, Wuxing Street, Xinyi District, Taipei City 110, Taiwan, China

5. Tabanan III Primary Health Care Service, Bali, Indonesia

6. Department of Cardiovascular Medicine, Mangusada General Hospital, Badung, Bali, Indonesia

### CORRESPONDING AUTHOR:

Gusti Ayu Riska Pertiwi  
Faculty of Medicine, Udayana University, P.B. Sudirman Street, Dangin Puri Klod, West Denpasar, Denpasar City, Bali 80232, Indonesia  
E-mail: pertiwaiyuriska@gmail.com

Received 16 July 2018;

Accepted 20 August 2018



## Introduction

Hypertension is generally accepted as one of the key modifiable risk factors for the development of cardiovascular diseases and cerebrovascular events [1–3]. Over the past 25 years, the growing aging population and some behavioral risk factors (e.g., unhealthy diet, physical inactivity, excess body weight, persistent stress) have inevitably contributed to a significant increase in the rate of elevated systolic blood pressure (SBP) and disability and deaths related to it. Thus hypertension is becoming a very important global health issue [2, 3].

Blood pressure (BP) inherently exhibits an array of spontaneous oscillations that can be seen as a neurohormonal adaptive response to internal and external stimuli. This fluctuation, known as *BP variability* (BPV), can happen in a short period (beat to beat, within 24 hours) or a long period (months, between visits) [4, 5]. Several clinical studies have recently suggested that higher short-term BPV, as measured by 24-hour ambulatory BP monitoring (ABPM), or long-term BPV, as measured by visit-to-visit variability (VTV), predicts poor prognosis not only for major cardiovascular events but also for other medical events [6, 7]. These include stroke [8], cognitive impairment [9], worsening renal function in a patient with or without chronic kidney disease [10–12], and development of microvascular complication in diabetes mellitus patients [13], independent of the average BP. Equally significant, apparently only studies on VTV have been done on the large scale of clinical trials, thus providing a stronger level of evidence than for ABPM [4, 14]. Moreover, head-to-head comparison between VTV and ABPM variability demonstrated that VTV might be a stronger prognostic predictor than ambulatory BPV in hypertensive patient. VTV could also provide more comprehensive information regarding long-term and ultra-long-term outcome in hypertensive patients [5, 15].

Although there are few discordant subsets of data regarding the prognostic relevance of each BPV measurement, it can be proposed that minimizing BPV may help to provide better cardiovascular protection in hypertensive patients. To achieve this goal, a more comprehensive measure should be used to overcome contributing factors. Unfortunately, data on factors responsible for the BPV observed between visits are very scarce and limited in the literature. A large observational randomized trial, the Antihypertensive and

Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), assessed the relationship between antihypertensive medication nonadherence and VTV and found a positive correlation [16]. Unfortunately, several risk factors that are assumed to correlate with hypertension, such as obesity, sodium intake, and levels of physical activity, remain unexplored. Only a paucity of evidence is available to explain the relationship between the factors mentioned above and BPV [17–19]. Considering sodium intake as an independent risk factor for VTV is unsatisfactory because of inconsistent findings [18, 19]. In one study that monitored ambulatory BP and physical activity in 431 patients, there was a significant association between physical activity and BPV, although this relationship is weak [20].

In the current study, we tried to explore factors affecting VTV in the real-world hypertensive population in a primary health care service setting. The primary health care service as the first gatekeeper in handling patients has a pivotal role in identifying modifiable risk factors for VTV of BP in hypertensive patients at the primary health care level. Hence concern for risk factor identification will provide an important benefit regarding the setting of health policy and prevention measures. For the reasons mentioned above, this study aimed to determine the factors associated with the VTV in BP at a primary health care service.

## Methods

### Study participants

Seventy-four hypertensive patients admitted to the outpatient clinic of the Tabanan III Primary Health Care Center, Tabanan, Bali, Indonesia, for evaluation and management of hypertension were enrolled in this study during April to May 2017. Hypertension was diagnosed on the basis of clinical measurements of SBP of 140 mm Hg or greater and/or diastolic BP (DBP) of 90 mm Hg or greater at a minimum of two different visits or if the patient was currently taking medication to control hypertension [21]. The patients' BP records over a 4-month period (January to April 2017) were retrieved, and those having fewer than three BP measurements from three different visits before data collection were excluded.

This study was evaluated and approved by the Ethics Committee, Faculty of Medicine, Udayana University, Bali,



Indonesia. Informed consent was obtained from all eligible participants who could provide informed consent.

### Data collection

**BP measurement, VVV of BP, and BP control:** Data regarding BP were retrospectively retrieved from medical records. BP was measured in office-based settings with an interval of 1–4 weeks by professional nurses with the conventional cuff method using a mercury sphygmomanometer (Nova-Presameter, Riester, Germany). In this study we used the standard deviation (SD) of BP from three to six visits as the main metric for VVV of SBP regardless of there being many other metrics available (coefficient of correlation, average real variability, SD independent of the mean [SDIM]) as studies found them to be equally significant. The SD of SBP was then classified into two groups by means of a cutoff point at the 50th percentile: values below the 50th percentile are defined as low variability of SBP and values equal to or greater than the 50th percentile are defined as high variability of SBP.

**Covariates:** Adherence to antihypertensive medication therapy was assessed through the percentage of days covered (PDC) at each visit. In this formula, the number of days the patient took the medication during a prescribed period (numbers of days in period “covered”) is divided by the number of days in the prescribed period, and then multiplied by 100.0%. Besides checking the pharmacy administrative database, we also asked directly whether participants had already taken their antihypertensive medications or not, to ensure the total number of days covered with medication was correct. Participants with PDC of less than 80.0% on at least one visit during the observation period were categorized as nonadherent (<96 days taking medication during 120 days of the prescribed period) [16]. Amlodipine and captopril were the medications used by the patients in this study.

Data on sodium intake were obtained through 24-hour food recall questions, the answers to which were analyzed with NutriSurvey 2007. These questions help in obtaining detailed information on all food, beverages, and dietary supplements taken by participants during the previous 24 hours, and questioning was done on two nonconsecutive days to estimate the participant’s mean usual dietary sodium intake.

Other potential variables that might affect VVV, including demographic, socioeconomic, and behavioral-related variables (smoking status, physical activity), comorbidity, and anthropometric data (height, weight, waist circumference, body mass index) were also analyzed. Smoking status was determined on the basis of smoking behavior currently and within the past year. The level of physical activity was categorized as sedentary, mild, or moderate according to the Centers for Disease Control and Prevention and American College of Sports Medicine 1999 guideline. Body mass index was calculated as weight (kg) divided by height squared ( $m^2$ ) [22].

### Statistical analysis

All statistical analyses were performed with IBM SPSS Statistics version 19. Participants’ characteristics, adherence to antihypertensive medication, sodium intake, and covariates were compared among the group with low VVV of SBP and the group with high VVV of SBP. Data were expressed as a percentage, mean  $\pm$  SD, or median (and range). Bivariate analysis using the chi-square test for dichotomous variables and the *t* test (parametric) and Mann-Whitney *U* test (non-parametric) was used to determine statistically significant differences between variables. All significant variables in the bivariate regression test were included in the multivariate regression test. Multivariable analysis was performed to calculate the  $\beta$  coefficient (standard error) and adjusted  $\exp \beta$  (odds ratio [OR], 95.0% confidence interval [CI]). Ultimately, the accuracy of the final significant variable was tested by receiver operating curve (ROC) analysis. We set  $P < 0.05$  as statistically significant.

## Results

### Baseline characteristics

Most of the participants were female (67.6%), and the mean (SD) age was 61.57 (9.82) years (range 45–81 years). The SBP and DBP were  $139.65 \pm 10.57$  mm Hg and  $84.52 \pm 6.10$  mm Hg, respectively, and were obtained from  $4.82 \pm 0.78$  measurements (range 3–7). The SD range of SBP was 5.77–23.09 mm Hg, and a median value of 10 mm Hg was used as a cutoff point to further classify participants into two groups; the group with low VVV of SBP and the group



with high VVV of SBP. The sodium intake per day, waist circumference, PDC, and body mass index were as follows:  $1387.14 \pm 451.98$  mg/day,  $84.81 \pm 8.41$  cm,  $99.82 \pm 15.81$  days, and  $25.49 \pm 4.07$  kg/m<sup>2</sup>, respectively. Only 16.2% patients had concurrent comorbidities (Table 1). Most of the participants were uneducated (58.1%), had mild activity level (67.6%), adhered to medication (74.3%), were married (89.2%), and had no smoking history (85.1%) (Table 1).

The characteristics of the patients in each study group are summarized in Table 2. The demographics, socioeconomic status, comorbidities, level of physical activity, smoking status, types of antihypertensive being used, and body mass index did not differ significantly between the low-VVV group and the high-VVV group. Poor adherence to the prescribed antihypertensive medications was more common in the high-VVV group than in the low-VVV group ( $P=0.030$ ). Participants in the high-VVV group also tended to have higher mean dietary sodium intake than those in the low-VVV group ( $P=0.038$ ) (Table 2).

### Multivariable analysis

The associations between study variables and VVV of SBP were further analyzed in a multivariate regression logistic test, and significance was found only for nonadherence to antihypertensive medications ( $P=0.023$ ). In multivariate model I, after adjustment for nonmodifiable covariates such as age and sex, nonadherence was significantly associated with high VVV of SBP (OR 3.89, 95.0% CI 1.23–12.34,  $P=0.021$ ) (Table 3). This result remained significant in full multivariable analysis (model II), which found that nonadherent patients had four times higher risk of having SD of SBP variability greater than 10 mm Hg (OR 4.22, 95.0% CI 1.22–14.64,  $P=0.023$ ) (Table 4). However, the area under the curve (AUC) in ROC analysis was 0.636 (95.0% CI 0.508–0.763,  $P=0.044$ ) (Fig. 1), which indicated that it had significantly weak discriminatory power to predict high BPV accurately. The sensitivity and specificity of this measurement were 67.6% and 51.4%, respectively.

### Discussion

VVV of BP was identified as an important independent risk factor for cardiovascular events and death in several studies.

Table 1. Demographic characteristics of participants at the Tabanan III Primary Health Care Service

Variable	Number	Mean $\pm$ SD
Sex		
Male	24.0 (32.4%)	
Females	50.0 (67.6%)	
Age (years)		61.57 $\pm$ 9.82
Marital status		
Married	66.0 (89.2%)	
Unmarried	0	
Widowed	8.0 (10.2%)	
Education		
Uneducated	43.0 (58.1%)	
Primary school	31.0 (41.9%)	
Junior high school	0	
Senior high school	0	
Undergraduate	0	
Level of physical activity		
Sedentary	24.0 (32.4%)	
Mild	50.0 (67.6%)	
Moderate	0	
High	0	
Treatment adherence		
Yes	55.0 (74.3%)	
No	19.0 (25.7%)	
Smoking		
Yes	11.0 (14.9%)	
No	63.0 (85.1%)	
Blood pressure (mm Hg)		
Systolic		139.65 $\pm$ 10.57
Diastolic		84.52 $\pm$ 6.10
Body mass index (kg/m <sup>2</sup> )		25.49 $\pm$ 4.07
Sodium intake (mg/day)		1387.14 $\pm$ 451.98
Waist circumference (cm)		84.81 $\pm$ 8.41
Measurement frequency (times)		4.82 $\pm$ 0.78
Comorbidities		
Yes	12.0 (16.2%)	
No	62.0 (83.8%)	
Percentage of days covered (%)		99.82 $\pm$ 15.81

However, recent studies still have a paucity of data regarding factors associated with VVV of BP. This study considered factors related to BPV between visits as measured by office BP in



Table 2. Characteristics of participants based on the level of visit-to-visit variability (VTV) of systolic blood pressure (SBP)

Characteristic	VTV of SBP		P value
	Low variability (n=37)	High variability (n=37)	
Age (years) (median [range])	61 (45–79)	65 (45–61)	0.468*
Sex (%)			
Male	35.1	29.7	0.801†
Marital status (%)			
Married	94.6	83.8	0.134†
Unmarried/divorced/widowed	5.4	16.2	
Currently working (%)			
No	35.1	40.5	0.811†
Economic status (%)			
Independent	35.1	51.4	0.159†
Dependent	64.9	48.6	
Education (%)			
Low	56.8	59.5	0.814†
Comorbidity (%)			
Yes	21.6	10.8	0.207†
Physical activity (%)			
Sedentary	29.7	35.1	0.619†
Mild	70.3	64.9	
Currently smoking (%)			
Yes	10.8	18.9	0.513†
Antihypertensive medication (%)			
Amlodipine	67.6	70.3	0.802
Captopril	49.9	42.2	0.815
Treatment adherence (%)			
No	13.5	37.8	0.030†
Sodium intake (mg) (mean ± SD)	1278.44 ± 430.22	1495.85 ± 452.62	0.038†
BMI (kg/m <sup>2</sup> ) (median [range])	24.5 (17.9–30.0)	24.6 (19.9–38.4)	0.783
WC (cm) (median [range])	84 (65–99)	84 (75–107)	0.265
SBP (mm Hg) (median [range])	144 (112–155)	152 (123–160)	0.174
DBP (mm Hg) (mean ± SD)	83.7 ± 6.25	85.32 ± 5.91	0.260‡

BMI, body mass index; DBP, diastolic blood pressure; WC, waist circumference.

\*Mann-Whitney *U* test.

†Chi-square test.

‡Independent *t* test.

hypertensive patients in a primary health care setting. The participants were essential hypertensive patients without apparent cardiovascular-related adverse complications, which makes this study suitable for analyzing the interaction between variables of interest and BPV at an earlier state of hypertension progression. The relatively low levels of concurrent noncardiac

comorbidities in the participants (only 16.2% had at least one comorbidity) mean that the results could be specifically attributed to hypertension itself.

The results of the present study results show that nonadherence to antihypertensive medication was independently associated with higher SBP variability between visits in



Table 3. Multivariate logistic regression results of study variables for high visit-to-visit variability patients

Variable	$\beta$	SE	P value
Age >60 years	-0.521	0.567	0.353
Male	-0.079	0.618	0.898
Single (unmarried/widowed/divorced)	0.792	0.313	0.32
Independent economic status	-0.945	0.579	0.103
Comorbidity	-1.851	0.918	0.056
Nonadherent	1.439	0.635	0.023*
Sodium intake >1364 mg	0.965	0.538	0.073

SE, standard error.

\*Significant ( $P < 0.05$ ).

Table 4. Odds ratios of adherence status for high visit-to-visit variability patients

	OR	95.0% CI	P value
Unadjusted	3.84	1.14–12.92	0.030
Model I*	3.89	1.23–12.34	0.021
Model II†	4.22	1.22–14.64	0.023

CI, confidence interval; OR, odds ratio.

\*Adjusted for age and sex.

†Adjusted for all variables in Table 2.




Fig. 1. Area under the curve of the receiver operating characteristic between nonadherence to medication (based on percentage of days covered) and high variability of blood pressure.

comparison with strict adherence to medication, and this remained significant after multivariate adjustment. A similar finding was obtained by Kronish et al. [16], who analyzed the ALLHAT population and used SDIM as their primary BPV index, and adherence was self-reported with guidance from the Adherence Survival Kit. After adjustment in multivariable analysis, nonadherent participants demonstrated 0.8 higher SDIM of SBP than adherent participants (95.0% CI 0.7–1.0,  $P < 0.001$ ). This result was similar for individuals who later changed to nonadherent from adherent (0.9; 95.0% CI 0.5–1.3,  $P < 0.001$ ), while those who became adherent conversely showed a 0.7 decrease in SDIM of SBP (95.0% CI -1.0 to -0.3,  $P < 0.001$ ) [16, 23]. Two studies that recruited a considerable number of participants, the African American Study of Kidney Disease and Hypertension (AASK) ( $n = 988$ ) [24] and a study that used data from the Cohort Study of Medication Adherence among Older Adults (CoSMO) ( $n = 1391$ ) [25], used pill count or pharmacy pill rates to define adherence into several categories. Both studies reported a linear association between poorer adherence and higher levels of variability. As a summary of these findings, despite the low accuracy of the nonadherence predictive model in the current study ( $AUC < 0.7$ ), addressing the level of adherence as a goal in a patient's therapeutic planning in addition to the conventional mean absolute BP at each visit will probably result in improvement of long-term outcomes in hypertensive patients.

One hypothesis proposed that the pharmacological actions of antihypertensive drugs being used may explain the associations observed between adherence and VVV. Some demonstrated superior action of calcium channel blockers (amlodipine) to reduce BPV [26–29]. The Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA) involving 19,257 high-BP patients revealed that the group taking amlodipine with or without perindopril had lower BPV between visits than the group taking atenolol with or without bendroflumethiazide. The effect on VVV further contributed to the risk reduction of stroke and coronary events in the aforementioned group [26]. Head-to-head comparison between amlodipine and other drugs (atenolol, lisinopril, chlorthalidone, and losartan) demonstrated a treatment difference of -1.23 mm Hg (0.46,  $P = 0.008$ ) by SD and -0.86 mm Hg (0.31,  $P = 0.005$ ) by coefficient of variation [29]. However, in



ALLHAT, no significant effect of medication classes on the nonadherence–high variability relationship was observed [16]. In our study, we found that the association between nonadherence and VVV was independent of the medication type used. Accordingly, these results provide a perspective on the complexity of the BPV and adherence relationship.

Other remaining covariates, such as demographic, socioeconomic, and behavioral-related factors, comorbidities, and anthropometrics, did not affect VVV. For intake of sodium, despite its well-known role in hypertension and established evidence that sodium restriction leads to substantial BP reduction [30], its association with VVV is still unclear. The present study found differences in sodium intake between each VVV group only when sodium intake was categorized as a continuous variable, whereas the association was no longer significant in categorical grouping and multivariate study. A study conducted by Diaz et al. [18] that recruited adequate numbers of individuals with high-normal DBP suggested that successful dietary sodium reduction during the study period (6 months) was not associated with decreased VVV of SBP with or without body weight reduction. Nevertheless, sodium intake regulation remains important in hypertension therapy, and it is imprudent not to consider it in deciding on the patient's management planning. Here we found the mean dietary sodium intake in both VVV groups was surprisingly below the recommendation from the World Health Organization (<2 g of sodium per day or <5 g of salt per day) and even far behind Asian population sodium intakes (>4.6 g/day). Our finding is similar to that of a study by Kamso et al. [31] in 2007 that involved a similar age group from samples of the Indonesian population (age 55–80 years), but they found inadequate mean sodium intakes of  $0.20 \pm 0.02$  g/day in males and  $0.16 \pm 0.02$  g/day in females.

### Study limitations

Several limitations may hinder the interpretation of our study findings. First, the total number of samples was rather small, making it impossible to classify BPV into more than two groups as in most prior studies, and thus this may mask actual association attributed to midclassification groups. Second, BP was retrospectively extracted from patients' medical records; there is a possibility that measurements were not conducted

following a standard protocol in some cases. Third, quantification of dietary sodium intakes using 24-hour food recall questions possess some limitations related to patient recall and some patients may underreport/overreport their diet. Fourth, there was a substantial difference in patient total visits and the time between visits, which could affect the SD of VVV observed in the population. Although there is no gold standard for the minimal number of visits needed to assess VVV, too few or too many total visits will inevitably correlate with VVV especially when expressed as SD of BP. Fifth, the current findings of VVV predict morbidity outcome only with a low level of evidence because of the predictive model ( $AUC < 0.7$ ), and therefore we suggest VVV can be used only to support diagnostic evidence.

### Conclusion

Nonadherence to antihypertensive medication is associated with higher VVV of SBP. VVV of BP has emerged as a supporting indicator in predicting morbidity and is diagnostic in hypertensive patients, and specific intervention targeting factors that affect variability is mandatory. Hence more studies are needed to evaluate the dynamic mechanisms underlying the associations between adherence and VVV, and whether improving factors related to VVV will also improve outcomes.

### Conflict of interest

The authors declare no conflict of interest.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Author contributions

Gusti Ayu Riska Pertiwi was responsible for data gathering and the methodological concept. Anak Agung Arya Wangsa was responsible for manuscript formation and final proofreading. I Putu Yuda Prabawa and Agha Bhargah were responsible for statistical analysis. Ida Bagus Amertha Putra Manuaba was responsible for revision of the manuscript and the methodological concept. Ni Wayan Sri Ratni, as an expert in community health in primary health care, and I Putu Gede Budiana, as an



expert in cardiology, provided guidance on the preparation of the manuscript.

## References

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2224–60.
2. Buford TW. Hypertension and aging. *Ageing Res Rev* 2016;26:96–111.
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *J Am Med Assoc* 2017;317(2):165–82.
4. Höcht C. Blood pressure variability: prognostic value and therapeutic implications. *ISRN Hypertens* 2013;2013:398485.
5. Mancia G. Short-and long-term blood pressure variability present and future. *Hypertension* 2012;60:512–7.
6. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study. *Ann Intern Med* 2015;163:329–38.
7. Eguchi K, Hoshida S, Joseph E, Schwartz JE, Shimada K, Kario K. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. *Am J Hypertens* 2012;25(9):962–8.
8. Nagai M, Kario K. Visit-to-visit blood pressure variability, silent cerebral injury, and risk of stroke. *Am J Hypertens* 2013;26(12):1369–76.
9. Qin B, Viera AJ, Munther P, Plassman BL, Edwards LJ, Adair LS, et al. Visit-to-visit variability in blood pressure is related to late-life cognitive decline. *Hypertension* 2016;68:106–13.
10. Chia YC, Lim HM, Ching SM. Long-term visit-to-visit blood pressure variability and renal function decline in patients with hypertension over 15 years. *J Am Heart Assoc* 2016;5(11):e003825.
11. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. *Am J Kidney Dis* 2014;64:714–22.
12. Magdás A, Szilágni L, Incze A. Can ambulatory blood pressure variability contribute to individual cardiovascular risk stratification. *Comput Math Methods Med* 2016;2016:7816830.
13. Sohn MW, Epstein N, Huang ES, Huo Z, Emanuele N, Stukenborg G, et al. Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. *J Diabetes Complications* 2017;31(1):195–201.
14. Campbell NR, Niebylski ML. Prevention and control of hypertension: developing a global agenda. *Curr Opin Cardiol* 2014;29(4):324–30.
15. Chenniappan M. Blood pressure variability: assessment, prognostic significance and management. *J Assoc Physicians India* 2015;63(5):47–53.
16. Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, et al. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Hypertension* 2016;68:39–45.
17. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. *Hypertension* 2011;57:160–6.
18. Diaz KM, Muntner P, Levitan EB, Brown MD, Babbitt DM, Shimbo D. The effects of weight loss and salt reduction on visit-to-visit blood pressure variability: results from a multicenter randomized controlled trial. *J Hypertens* 2014;32(4):840–8.
19. Iuichi H, Sakamoto M, Suzuki H, Kayama Y, Ohashi K, Hayashi T. Effect of one-week salt restriction on blood pressure variability in hypertensive patients with type 2 diabetes. *PLoS One* 2016;11(1):e0144921.
20. Leary AC, Donnan PT, MacDonald TM, Murphy MB. The influence of physical activity on the variability of ambulatory blood pressure. *Am J Hypertens* 2000;13(10):1067–73.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *J Am Med Assoc* 2003;289(19):2560–72.
22. Pate RR, Blair SN, Pratt M, King AC. A recommendation from The Center for Disease Control and Prevention and the American College of Sports Medicine. *JAMA* 1999;273(5):402–7.
23. Hastie CE, Jeemon P, Coleman H, McCallum L, Patel R, Dawson J, et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14 522 patients with hypertension. *Hypertension* 2013;62:698–705.
24. Hong K, Muntner P, Kronish I, Shilane D, Chang TI. Medication adherence and visit-to-visit variability of systolic blood pressure





- in African Americans with chronic kidney disease in the AASK trial. *J Hum Hypertens* 2016;30(1):73–8.
25. Muntner P, Levitan EB, Joyce C, Holt E, Mann D, Oparil S, et al. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. *J Clin Hypertens (Greenwich)* 2013;15(2):112–7.
  26. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium channel blockers on within individual variability in blood pressure and risk of stroke. *Lancet Neurol* 2010;9(5):469–80.
  27. Aalbers J. Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk. *Cardiovasc J Afr* 2010;21(2):115–6.
  28. Kollias A, Stergiou GS, Kyriakoulis KG, Bilo G, Parat G. Treating Visit-to-visit blood pressure variability to improve prognosis: is amlodipine the drug of choice? *Hypertension* 2017;70:862–6.
  29. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long term blood pressure variability: evidence from randomized controlled trials. *J Am Soc Hypertens* 2014;8(5):340–9.
  30. Obarzanek E, Proschan MA, Vollmer WM, Moore TJ, Sacks FM, Appel LJ, et al. Individual blood pressure response to changes in salt intake, results from DASH-Sodium trial. *Hypertension* 2003;42:459–67.
  31. Kamso S, Rumawas JS, Lukito W, Purwastyastuti P. Determinants of blood pressure among Indonesian elderly individuals who are of normal and overweight: a cross sectional study in an urban population. *Asia Pac J Clin Nutr* 2007;16:545–53.